AVANT Immunotherapeutics was formed in May 1998, through the acquisition of Virus Research Institute by T Cell Sciences. AVANT targets its efforts where it can add the greatest value to the development of its products and technologies. It's goal is to demonstrate clinical proof-of-concept for each product, and when appropriate seek excellent partners to help see those products through to commercialization. This approach allows the company to maximize the overall value of its technology and product portfolios while best ensuring the expeditious development of each individual product. The company has actively developed and acquired innovative technologies - especially novel approaches to vaccine creation. Today its broad intellectual property position allows it to respond quickly and leverage its expertise into many different areas as opportunities and needs arise. For example, the company's vaccine technology for providing rapid protection against bacterial illnesses may prove useful for improving and expanding America's vaccine arsenal against microbial agents used in war or terrorist attacks.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.